1
|
Ikeda H, Takai M, Tsujiuchi T. Lysophosphatidic acid (LPA) receptor-mediated signaling and cellular responses to anticancer drugs and radiation of cancer cells. Adv Biol Regul 2024; 92:101029. [PMID: 38377635 DOI: 10.1016/j.jbior.2024.101029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2024] [Revised: 01/30/2024] [Accepted: 02/08/2024] [Indexed: 02/22/2024]
Abstract
Lysophosphatidic acid (LPA) is a simple physiological lipid and structurally consists of a fatty, a phosphate and a glycerol. LPA binds to G protein-coupled LPA receptors (LPA1 to LPA6). LPA receptor-mediated signaling mediates a variety of biological responses, such as cell growth, migration, morphogenesis, differentiation and protection from apoptosis. It is considered that LPA receptor-mediated signaling plays an important role in the pathogenesis of human malignancies. So far, genetic and epigenetic alterations of LPA receptors have been found in several cancer cells as well as abnormal LPA production. In addition, LPA receptor-mediated signaling regulates the promotion of malignant behaviors, including chemo- and/or radiation-resistance. Chemotherapy and radiotherapy are the common approaches to the treatments of cancers. However, resistance to anticancer drugs and irradiation is the most critical limitation for chemotherapy and radiotherapy. In this review, we provide the roles of LPA receptor-mediated signaling in the regulation of cellular responses induced by chemotherapeutic agents and irradiation and its biological utility as a possible molecular target for improving cancer cell responses to chemotherapy and radiotherapy.
Collapse
Affiliation(s)
- Hiroko Ikeda
- Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kindai University, 3-4-1, Kowakae, Higashiosaka, Osaka 577-8502, Japan
| | - Miwa Takai
- Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kindai University, 3-4-1, Kowakae, Higashiosaka, Osaka 577-8502, Japan
| | - Toshifumi Tsujiuchi
- Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kindai University, 3-4-1, Kowakae, Higashiosaka, Osaka 577-8502, Japan.
| |
Collapse
|
2
|
Wang S, Chen J, Guo XZ. KAI1/CD82 gene and autotaxin-lysophosphatidic acid axis in gastrointestinal cancers. World J Gastrointest Oncol 2022; 14:1388-1405. [PMID: 36160748 PMCID: PMC9412925 DOI: 10.4251/wjgo.v14.i8.1388] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/11/2021] [Revised: 01/06/2022] [Accepted: 07/22/2022] [Indexed: 02/05/2023] Open
Abstract
The KAI1/CD82 gene inhibits the metastasis of most tumors and is remarkably correlated with tumor invasion and prognosis. Cell metabolism dysregulation is an important cause of tumor occurrence, development, and metastasis. As one of the important characteristics of tumors, cell metabolism dysregulation is attracting increasing research attention. Phospholipids are an indispensable substance in the metabolism in various tumor cells. Phospholipid metabolites have become important cell signaling molecules. The pathological role of lysophosphatidic acid (LPA) in tumors was identified in the early 1990s. Currently, LPA inhibitors have entered clinical trials but are not yet used in clinical treatment. Autotaxin (ATX) has lysophospholipase D (lysoPLD) activity and can regulate LPA levels in vivo. The LPA receptor family and ATX/lysoPLD are abnormally expressed in various gastrointestinal tumors. According to our recent pre-experimental results, KAI1/CD82 might inhibit the migration and metastasis of cancer cells by regulating the ATX-LPA axis. However, no relevant research has been reported. Clarifying the mechanism of ATX-LPA in the inhibition of cancer metastasis by KAI1/CD82 will provide an important theoretical basis for targeted cancer therapy. In this paper, the molecular compositions of the KAI1/CD82 gene and the ATX-LPA axis, their physiological functions in tumors, and their roles in gastrointestinal cancers and target therapy are reviewed.
Collapse
Affiliation(s)
- Shuo Wang
- Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang 110840, Liaoning Province, China
| | - Jiang Chen
- Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang 110840, Liaoning Province, China
| | - Xiao-Zhong Guo
- Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang 110840, Liaoning Province, China
| |
Collapse
|
3
|
Yoshikawa K, Tanabe E, Shibata A, Inoue S, Kitayoshi M, Okimoto S, Fukushima N, Tsujiuchi T. Involvement of oncogenic K-ras on cell migration stimulated by lysophosphatidic acid receptor-2 in pancreatic cancer cells. Exp Cell Res 2012; 319:105-12. [PMID: 23041208 DOI: 10.1016/j.yexcr.2012.09.014] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2012] [Revised: 09/25/2012] [Accepted: 09/27/2012] [Indexed: 12/30/2022]
Abstract
Lysophosphatidic acid (LPA) mediates a variety of cellular responses with atleast six G protein-coupled transmembrane receptors (LPA receptor-1 (LPA(1)-LPA(6))). The interaction between LPA receptors and other cellular molecules on the biological function is not fully understood. Recently, we have reported that LPA(1) suppressed and LPA(3) stimulated cell migration of pancreatic cancer cells. In the present study, to evaluate the function of LPA(2) on motile and invasive activities of pancreatic cancer cells, we generated Lpar2 knockdown (HPD-sh2) cells from hamster pancreatic cancer cells and measured their cell migration ability. In cell motility and invasive assays with an uncoated Cell Culture Insert, HPD-sh2 cells showed significantly lower intrinsic activity than control (HPD-GFP) cells. Since K-ras mutations were frequently detected in pancreatic cancer, we next investigated whether oncogenic K-ras is involved in cell migration induced by LPA(2) using K-ras knockdown (HPD-K2) cells. The cell motile ability of HPD-K2 cells was significantly lower than that of control cells. To confirm LPA(2) increases cell migration activity, cells were pretreated with dioctylglycerol pyrophosphate (DGPP) which is the antagonist of LPA(1)/LPA(3). The cell motile and invasive abilities of DGPP -treated HPD-GFP cells were markedly higher than those of untreated cells, but DGPP did not stimulate cell migration of HPD-K2 cells. These results suggest that cell migration activity of pancreatic cancer cells stimulated by LPA(2) may be enhanced by oncogenic K-ras.
Collapse
Affiliation(s)
- Kyohei Yoshikawa
- Division of Cancer Biology and Bioinformatics, Department of Life Science, Faculty of Science and Engineering, Kinki University, Higashiosaka, Osaka, Japan
| | | | | | | | | | | | | | | |
Collapse
|
4
|
Opposite roles of LPA1 and LPA3 on cell motile and invasive activities of pancreatic cancer cells. Tumour Biol 2012; 33:1739-44. [DOI: 10.1007/s13277-012-0433-0] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2012] [Accepted: 05/28/2012] [Indexed: 12/30/2022] Open
|
5
|
Differential function of lysophosphatidic acid receptors in cell proliferation and migration of neuroblastoma cells. Cancer Lett 2012; 316:91-6. [DOI: 10.1016/j.canlet.2011.10.030] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2011] [Revised: 09/15/2011] [Accepted: 10/20/2011] [Indexed: 01/24/2023]
|
6
|
Tsujiuchi T, Okabe K, Fukushima N. Genetic and epigenetic alterations of lysophosphatidic Acid receptor genes in rodent tumors by experimental models. J Toxicol Pathol 2011; 24:143-8. [PMID: 22272054 PMCID: PMC3234590 DOI: 10.1293/tox.24.143] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2011] [Accepted: 06/06/2011] [Indexed: 12/31/2022] Open
Abstract
Lysophosphatidic acid (LPA) is a bioactive mediator and induces several biological effects, including cell proliferation, migration, morphogenesis and differentiation. LPA interacts with at least six G protein-coupled receptors (GPCRs), including LPA receptor-1 (LPA(1)), LPA(2), LPA(3), LPA(4), LPA(5) and LPA(6). These receptors show different biological functions through the binding of LPA, depending on the type of cells. In human malignancies, a high level of LPA production was found in plasma and ascites in ovarian cancer cases. Moreover, aberrant expression levels of LPA receptor genes were detected in some cancer cells. Therefore, it is suggested that LPA receptors may be involved in the pathogenesis of tumor cells as well as LPA per se. Recently, we have reported that alterations of LPA receptor genes also occur in rodent tumors. In this review, we summarize the recent evidence in the investigations of LPA receptor alterations in rodent tumors by experimental models.
Collapse
Affiliation(s)
- Toshifumi Tsujiuchi
- Division of Cancer Biology and Bioinformatics,
Department of Life Science, Faculty of Science and Engineering, Kinki
University, 3-4-1 Kowakae, Higashiosaka, Osaka 577-8502, Japan
| | - Kyoko Okabe
- Division of Cancer Biology and Bioinformatics,
Department of Life Science, Faculty of Science and Engineering, Kinki
University, 3-4-1 Kowakae, Higashiosaka, Osaka 577-8502, Japan
| | - Nobuyuki Fukushima
- Division of Molecular Neurobiology, Department of
Life Science, Faculty of Science and Engineering, Kinki University, 3-4-1
Kowakae, Higashiosaka, Osaka 577-8502, Japan
| |
Collapse
|
7
|
Wakabayashi N, Tsujino M, Tajiri M, Taki M, Koshino A, Ikeda H, Fukushima N, Tsujiuchi T. No Mutations of Lysophosphatidic Acid Receptor Genes in Lung Adenocarcinomas Induced by N-Nitrosobis(2-hydroxypropyl)amine in Rats. J Toxicol Pathol 2010; 23:63-6. [PMID: 22272013 PMCID: PMC3234649 DOI: 10.1293/tox.23.63] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2009] [Accepted: 11/19/2009] [Indexed: 01/08/2023] Open
Abstract
Lysophosphatidic acid (LPA) is a bioactive phospholipid that stimulates cell
proliferation and migration, and protects cells from apoptosis. It interacts
with specific G protein-coupled transmembrane receptors. Recently, frequent
mutations of the LPA receptor-1 (LPA1) gene were detected in rat lung
adenocarcinomas induced by N-nitrosobis(2-hydroxypropyl)amine (BHP). In this
study, to evaluate the involvement of other LPA receptor gene alterations during
lung carcinogenesis, we investigated mutations of the LPA2, LPA3, LPA4 and LPA5
genes in lung adenocarcinomas induced by BHP in rats. Fifteen male Wistar rats,
6 weeks of age, were given 2000 ppm BHP in their drinking water for 12 weeks and
then maintained without further treatment until sacrifice at 25 weeks, and 15
adenocarcinomas were obtained. Genomic DNAs were extracted from frozen tissues,
and the LPA2, LPA3, LPA4 and LPA5 genes were examined for mutations, using
polymerase chain reaction (PCR)-single strand conformation polymorphism (SSCP)
analysis. No mutations of LPA2, LPA3, LPA4 and LPA5 were detected in the 15
adenocarcinomas. These results suggest that alterations due to LPA2, LPA3, LPA4
and LPA5 gene mutations might not be involved in the development of lung
adenocarcinomas induced by BHP in rats.
Collapse
Affiliation(s)
- Naoko Wakabayashi
- Laboratory of Cancer Biology and Bioinformatics, Department of
Life Science, Faculty of Science and Engineering, Kinki University, 3–4–1
Kowakae, Higashiosaka, Osaka 577-8502, Japan
| | - Megumu Tsujino
- Laboratory of Cancer Biology and Bioinformatics, Department of
Life Science, Faculty of Science and Engineering, Kinki University, 3–4–1
Kowakae, Higashiosaka, Osaka 577-8502, Japan
| | - Masaki Tajiri
- Laboratory of Cancer Biology and Bioinformatics, Department of
Life Science, Faculty of Science and Engineering, Kinki University, 3–4–1
Kowakae, Higashiosaka, Osaka 577-8502, Japan
| | - Midori Taki
- Laboratory of Cancer Biology and Bioinformatics, Department of
Life Science, Faculty of Science and Engineering, Kinki University, 3–4–1
Kowakae, Higashiosaka, Osaka 577-8502, Japan
| | - Ayumi Koshino
- Laboratory of Cancer Biology and Bioinformatics, Department of
Life Science, Faculty of Science and Engineering, Kinki University, 3–4–1
Kowakae, Higashiosaka, Osaka 577-8502, Japan
| | - Hiroko Ikeda
- Laboratory of Cancer Biology and Bioinformatics, Department of
Life Science, Faculty of Science and Engineering, Kinki University, 3–4–1
Kowakae, Higashiosaka, Osaka 577-8502, Japan
| | - Nobuyuki Fukushima
- Laboratory of Molecular Neurobiology, Department of Life
Science, Faculty of Science and Engineering, Kinki University, 3–4–1 Kowakae,
Higashiosaka, Osaka 577-8502, Japan
| | - Toshifumi Tsujiuchi
- Laboratory of Cancer Biology and Bioinformatics, Department of
Life Science, Faculty of Science and Engineering, Kinki University, 3–4–1
Kowakae, Higashiosaka, Osaka 577-8502, Japan
| |
Collapse
|